Document is current
Any future updates will be listed below
-
Authors
Boesecke, Christoph
Workowski, Kimberly
Gordon, Stuart C.
Cave, Barbra
Marcinak, John
Miller, Michael G.
Semizarov, Dimitri
Welhaven, Anne
Baumgarten, Axel
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04903626 at ClinicalTrials.govDocuments that mention this clinical trial
Glecaprevir/Pibrentasvir for Acute Hepatitis C Virus Infection in Individuals with a History of Prior Hepatitis C Infection
https://doi.org/10.1007/s40121-026-01381-w
-
Funding
Funding for this research was provided by:
AbbVie
- License Information
-
More Information
Article History
Received: 16 March 2026
Accepted: 28 May 2026
First Online: 24 June 2026
Declarations
:
: Christoph Boesecke received honoraria for consulting or speaking at educational events from Gilead, AbbVie, MSD, ViiV/GSK, Pfizer, AstraZeneca, and Bavarian Nordic. Kimberly Workowski received institutional research funding from AbbVie. Stuart C. Gordon received honoraria for consulting or speaking from Gilead, Ipsen, AbbVie, and Mirum. Barbra Cave, John Marcinak, Michael G. Miller, Dimitri Semizarov, and Anne Welhaven are employees of AbbVie and may own stock. Axel Baumgarten received honoraria for consulting or speaking at educational events from Gilead, AbbVie, MSD, ViiV/GSK, Pfizer, and AstraZeneca.
: This article is based on a previously conducted study [ ], which was performed in accordance with the International Council for Harmonisation Good Clinical Practice guidelines and principles of the Declaration of Helsinki or the laws and regulations of the regions in which the research was performed. The study was approved by the institutional review boards or independent ethics committees of the participating sites. Written informed consent was obtained from all study participants.
